PLRX250117P30000
- 0.00
- 0.000.00%
Pliant Therapeutics Newsroom
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Leerink Partners Maintains Pliant Therapeutics(PLRX.US) With Buy Rating, Maintains Target Price $33
Positive Developments in Pliant Therapeutics' IPF Research Bolster Buy Rating
Pliant Therapeutics Reports Increased Losses and Strategic Focus
Express News | Pliant Therapeutics Plans To Present Data From Bexotegrast Program At Liver Meeting 2024
Pliant Therapeutics Presents Data From Its Bexotegrast Program at The Liver Meeting 2024
Pliant Therapeutics Insiders Sold US$574k Of Shares Suggesting Hesitancy
A Quick Look at Today's Ratings for Pliant Therapeutics(PLRX.US), With a Forecast Between $32 to $45
Pliant Therapeutics Price Target Maintained With a $38.00/Share by HC Wainwright & Co.
Pliant Therapeutics Analyst Ratings
RBC Capital Maintains Pliant Therapeutics(PLRX.US) With Buy Rating, Maintains Target Price $45
Needham Maintains Pliant Therapeutics(PLRX.US) With Buy Rating, Maintains Target Price $38
Positive Outlook on Pliant Therapeutics: Strategic Developments and Financial Stability Support Buy Rating
TD Cowen Maintains Pliant Therapeutics(PLRX.US) With Buy Rating
Pliant Therapeutics (PLRX) Receives a Buy From TD Cowen
Pliant Therapeutics Reports Q3 EPS (95c), Consensus (97c)
Pliant Therapeutics | 10-Q: Q3 2024 Earnings Report
Pliant Therapeutics | 8-K: Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Express News | Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results